Parkinson Mortality Rate Was 72 per 100,000 in 2024 - Report - MDSpire

Parkinson Mortality Rate Was 72 per 100,000 in 2024

The age-adjusted Parkinson disease death rate among US adults aged 65 years and older was 72.0 deaths per 100,000 standard population in 2024, lower than the 2021 rate, according to a National Center for Health Statistics Data Brief.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 4 min

Share

Clinical Report: Parkinson Mortality Rate Was 72 per 100,000 in 2024

Overview

In 2024, the age-adjusted mortality rate for Parkinson disease among US adults aged 65 and older was 72.0 per 100,000. This represents a decline from 76.3 in 2021, although the trend from 2021 to 2024 was not statistically significant according to the analysis.

Background

Parkinson disease is a significant public health concern, being the ninth leading cause of death among older adults in the US.

Data Highlights

YearAge-Adjusted Death Rate (per 100,000)
201457.2
202176.3
202472.0

Key Findings

  • Parkinson disease accounted for 39,935 deaths among adults aged 65 and older in 2024.
  • The age-adjusted death rate for Parkinson disease was 72.0 per 100,000 in 2024.
  • Death rates were approximately twice as high in men (105.6) compared to women (47.6).
  • Age-adjusted death rates increased with age, reaching 227.0 among those aged 85 and older.
  • White non-Hispanic adults had the highest age-adjusted death rate at 81.7 per 100,000.
  • State-level mortality rates varied significantly, from 47.7 in New York to 102.1 in Utah.

Clinical Implications

The findings highlight the need for targeted interventions and resources for older adults with Parkinson disease, particularly among men and specific racial groups. Clinicians should be aware of the increasing mortality risk associated with advancing age in this population.

Related Resources & Content

  1. CDC National Center for Health Statistics, NCHS Data Brief 563, 2024 -- Parkinson Mortality Rate Was 72 per 100,000 in 2024
  2. Frontiers in Psychiatry — Incidence of anxiety disorders following Parkinson's disease: a population-based cohort study
  3. Drugs - Real World Outcomes — Financial Impact of Parkinson’s Disease: A Comprehensive, International Cost-of-Illness Analysis
  4. Frontiers in Neurology — Evidence for exponential progression in advanced Parkinson’s disease: retrospective analysis of a prospective cohort study
  5. Drug Safety — Comparative Mortality Rates in Parkinson’s Disease-Related Psychosis Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cohort Analysis
  6. NCHS Data Brief 563
  7. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease
  8. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial - ScienceDirect

Original Source(s)

Parkinson Mortality Rate Was 72 per 100,000 in 2024

  • by Kathryn Wighton

  • June 29, 2026

Related Content

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls